Vol. 6, Issue 1, Part B (2024)

Introduction: The following study has discussed how metformin is employed for different types of diabetes as an “antidiabetic therapy”. It explains how chronic hyperglycemia damages organs, and how metformin helps reduce glucose levels by decreasing absorption and enhancing insulin sensitivity. The study also mentions the importance of HbA1c and fasting plasma glucose for measuring glycemic control.
Aims and Objectives: To evaluate the changes in respiratory physiology in patients receiving metformin therapy.
Methods: To conduct this research, the researcher used ANOVA statistical software. By implementing this statistical software, the researcher was able to properly compare % between different groups through Chi-square, the student's t-test, with the similar average scores. This research was completed among adults who were the age groups from 18-75 as well as suffered with Insufficient Glucose Tolerance (IGT), severe COPD, BMI >25, kg/m2, and nutrition type 2 diabetic mellitus (T2DM).
Result: Through this study, the researcher used different kinds of statistical data, ANOVA statistical software, and tables to complete this research. Again, this study has been approved by the hospital's ethical review board. Furthermore, this research included individuals in the age group from 18 to 75 who were obese with COPD symptoms. On the other hand, the clinical trial showed the effectiveness of metformin in reducing fasting plasma glucose levels.
Conclusion: Metformin was an effective antidiabetic therapy with potential benefits for COPD. It Combined with GLP-1R agonists improves airway inflammation and bronchoconstriction. Metformin was well-tolerated with no significant adverse effects.